The Salk Institute for Biological Studies

Baylor College of Medicine

Ligand Pharmaceuticals, Inc.

Other

Christina Thaller

Ronald Mark Evans

Marcus F Boehm

Richard Alan Heyman

David John Mangelsdorf

Gregor Eichele

In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.

Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor

A method for modulating lipid metabolism in a subject by administering 9-cis retinoic acid is presented. The 9-cis retinoic acid is more specific for the retinoid X receptor than is retinoic acid.

Means for the modulation of processes mediated by retinold receptors and compounds useful therefor

Compounds and compositions useful for modulation of processes mediated by RXR

Means for the modulation of processes mediated by retinoid receptors and

A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.

Method for in vivo modulation of non-malignant skin-related processes

Growing community of inventors

Houston, TX, United States of America

Christina Thaller